⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Eczacıbaşı Group and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Eczacıbaşı Group
↗Istanbul, Turkey
Eczacıbaşı is a prominent Turkish industrial conglomerate founded in 1942. The group operates across diverse sectors including building products, healthcare and pharmaceuticals, consumer products, natural resources, finance, and information technology.
In the healthcare sector, Eczacıbaşı is a major player in Turkey, focusing on pharmaceutical marketing, distribution, and the development of radiopharmaceuticals. The group maintains a robust portfolio of both generic and branded drugs, with a strong emphasis on oncology, rare diseases, and central nervous system disorders.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Pharmaceutical Marketing and Distribution
SIZE & FINANCIALS
Employees:10000+
Revenue:$1B-$2B
Founded:1942
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Radiopharmaceuticals, Biosimilars
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Eczacıbaşı Pharmaceuticals Marketing, Gensenta, Eczacıbaşı-Monrol, Eczacıbaşı Bilişim
Key Partnerships:Baxter International (Hospital products), Zydus Cadila (Biosimilars), Telix Pharmaceuticals (Radiopharmaceuticals)
COMPETITION
Position:Leader
Competitors:Abdi İbrahim, Deva Holding, Koçak Farma
LEADERSHIP
Key Executives:
Bülent Eczacıbaşı - Chairman
Atalay M. Gümrah - CEO
LINKS
Website:support.eczacibasi.com.tr
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Eczacıbaşı Group. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.